Advertisement
Advertisement
U.S. markets close in 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Galectin Therapeutics Inc. (GALT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.31000.0000 (0.00%)
As of 02:41PM EDT. Market open.
Advertisement
Sign in to post a message.
  • B
    BaddaBing
    I follow a handful of random biotech companies that also fell almost 10% yesterday. None of them had any news to cause a drop. I actually like to see that others a falling because the price action now makes zero sense. I can't buy anymore here, but I certainly won't sell.
  • S
    ScorpionLeather
    @B Should explain why he thinks the first patients are not in Phase 3 if the press release says that they are in Phase 3. This is more proof of B's attempts at denying reality.

    “The first patients in NAVIGATE have now reached their 18-month visit and have elected to continue into the extension phase of the phase 3 part of NAVIGATE. This is an additional significant milestone for the belapectin development program as we are now starting to collect follow-up data beyond a year and a half of treatment to further inform the benefit risk of belapectin in cirrhotic patients.”
    Bullish
  • L
    Leanne
    Sorry to say, whoever sold this stock today will deeply regret in very near future. Those patents are not advertised but those are actions.
  • S
    ScorpionLeather
    Link to the presentation livestream:

    Live on Tuesday, 5/24 at 7:00 AM (Eastern Standard Time)

    https://journey.ct.events/view/552fc2e6-73ca-4748-8a49-63a880925423
    Journey
    journey.ct.events
    Bullish
  • N
    Neil
    tomorrow I continue adding volume will continue to increase should be at least 200,000 to a quarter mil👁️
  • L
    Leanne
    Look past the kids fighting on this board. All of the news from the company is very good.
  • L
    LGALS3
    United States Patent Application 20220144798 May 12, 2022
    Novartis AG
    30. A method of treating cancer comprising administering to the patient in need thereof a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
    31. The method according to claim 30, wherein the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myelogenous leukemia, and gastrointestinal stromal tumor (GIST).
    32. The method according to claim 30, wherein the cancer is a cancer for which the immune response is deficient or an immunogenic cancer.

    [0958] In some embodiments, the Galectin, e.g., Galectin-1 or Galectin-3, inhibitor is a carbohydrate based compound. In some embodiments, the Galectin inhibitor is GR-MD-02 (Galectin Therapeutics). In some embodiments, GR-MD-02 is a Galectin-3 inhibitor. GR-MD-02 is a galactose-pronged polysaccharide also referred to as, e.g., a galactoarabino-rhamnogalaturonate. GR-MD-02 and other galactose-pronged polymers, e.g., galactoarabino-rhamnogalaturonates, are disclosed in U.S. Pat. No. 8,236,780 and U.S. Publication 2014/0086932, the entire contents of which are herein incorporated by reference in their entirety.
    Bullish
  • L
    LGALS3
    Update on clinicaltrials.gov,
    The Paris France site has completed the
    phase 2b trial, it's on to phase 3.
    Bullish
  • L
    LGALS3
    A multi-center cancer immunotherapy clinical trial catalyst is in the making,
    “Additionally, we are making progress and are working to compile an Investigational New Drug (IND) package, including the development of a phase 2 trial protocol, with the objective for the Company to file an IND with the FDA oncology division for the treatment of recurrent or metastatic head and neck cancer for belapectin in combination with Keytruda®, an immune checkpoint inhibitor."
    Bullish
  • A
    Anonymous
    Just to review for the members of this board the potential problems of ICPT as a NASH drug

    1) Minimal efficacy- and now all biopsies now being reread with Artificial Intelligence. Data might not be true
    2) AASLD position paper just out saying ICPT drug should be used in caution in cirrhosis (already has black box warning in decompensated cirrhosis). A portion of F3 NASH silently and rapidly accelerate to cirrhosis. Could be dangerous
    3) FGF19 cancer concerns, especially as a portion of HCC is FGF19 driven. ICPT works via FGF19
    4) Shift in Hepatology to clinical outcomes, rather than Histopathology- see Dr. Boudes recent discussion on that in GALT earnings call

    Doesn't look like ICPT will make it for NASH

    Just my opinion. Good drug for PBC. NASH? I don't think so
  • S
    ScorpionLeather
    Here is what the world's top researchers are saying about GALT belapectin in recent months. These are publications from the top journals:

    -----

    Macrophage functional diversity in NAFLD — more than inflammation
    Journal Nature - 09 May 2022

    "Galectin 3 is mainly expressed by macrophages and its inhibition has beneficial effects on fibrosis development. The inhibitor belapectin (GR- MD-02) was tested in clinical trials and was effective in reducing portal hypertension and fibrosis. Another trial is currently ongoing to confirm these results."

    -----

    Current and emerging therapies for the management of cirrhosis and its complications
    (Authored by world’s top liver KOLs)
    Wiley AP&T - 02 March 2022
    “ A randomised phase 2b trial of belapectin, … , belapectin reduced hepatic venous pressure gradient and improved fibrosis”

    -----

    Profile of Plasma Galectin-3 Concentrations, Inflammatory Cytokines Levels and Lymphocytes Status in Breast Cancer under Chemotherapy
    Journal of Immunology Vol.12 No.1,March 22, 2022

    "Moreover, gal-3 is also an interesting potential target in anticancer therapy. So far, there is no published data from clinical trials of galectin-3 blockade therapy in breast neoplasms. However, the use of the combination of gal-3 inhibitor the GR-MD-02 with pembrolizumab (anti-PD-1 monoclonal antibody) has shown encouraging results in patients with melanoma and HNSCC (Head and Neck Squamous Cell Carcinoma). The immune-mediated adverse events were reduced in comparison with pembrolizumab used alone [18]. The same strategies could be adopted in breast neoplasms: combining galectin-3 inhibitors with existing immunotherapy."

    -----

    Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
    Texas MD Anderson Cancer Center, Houston, TX, USA
    Nature Communications volume 13, Article number: 42 (2022)

    “Third, belapectin, an inhibitor of the encoded protein of LGALS3 (top 8.78% in our prediction), can enhance the clinical and immunological effects of anti-PD178. All these demonstrated that our approach can effectively identify genes and pathways associated with response to anti-PD-1 therapy in cancer.“

    -----

    Therapeutic implications of galectin-3 in patients with atrial fibrillation
    Lee et al.
    Journal Nature – 17 January 2022
    This new paper in the journal Nature, Therapeutic implications of galectin-3 in patients with atrial fibrillation, (17 Jan 2022) is referring to GALT's GM-CT-01:

    "Recently, inhibition of galectin-3 reduced atrial fibrosis and the total burden of atrial fibrillation."

    -----

    Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
    Published online 2021 Mar 1.

    OncoImmunology

    “Combination aOX40/belapectin therapy enhanced CD8+ T cell density within the tumor and reduced the frequency and proliferation of regulatory Foxp3+CD4+ T cells. Further, aOX40/belapectin therapy significantly reduced monocytic MDSC (M-MDSCs) and MHC-IIhi macrophage populations, both of which displayed reduced arginase 1 and increased iNOS. Combination aOX40/belapectin therapy alleviated M-MDSC-specific functional suppression compared to M-MDSCs isolated from untreated tumors. Our data suggests that Gal-3 inhibition plus aOX40 therapy reduces M-MDSC-meditated immune suppression thereby increasing CD8+ T cell recruitment leading to increased tumor regression and survival.”

    -----

    Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
    2021 April
    Journal for Immunotherapy for Cancer

    “In summary, these data demonstrate that belapectin+pembrolizumab therapy is safe, associated with increased T-cell activation, limited expansion of M-MDSCs, and favorable clinical responses. We propose that in the absence of therapy, PD-L1 and Gal-3 contribute to M2-macrophage polarization and reduced CD8+ T-cell recruitment to the tumor site (figure 6). In the presence of PD-1 blockade, CD8+ T cells can be reinvigorated, but suppressed due to other inhibitory signals. In contrast, combination belapectin+pembrolizumab therapy enables T-cell activation in the presence of a more proinflammatory TME capable of supporting T-cell effector function and recruitment, and subsequently tumor regression.
    “Comprehensive immune profiling revealed candidate biomarkers of immune response including tumor-specific Gal-3 expression and PD-1+ effector memory T cells that appeared to enrich for patients more likely to respond to belapectin+pembrolizumab treatment. Furthermore, mass spectrometry analysis revealed that trough levels of pembrolizumab in the serum could also serve as a potential biomarker for clinical outcome. These data provide a strong rationale to perform a randomized placebo-controlled phase II clinical trial to evaluate the efficacy and immune changes of belapectin+pembrolizumab versus pembrolizumab in patients with MM or HNSCC.”
    Bullish
  • A
    Anonymous
    Ed Arce called ICPT correctly.

    As far as GALT, Ed Arce still has a buy on it but revised the price target - possibly to reflect current Bio valuations.

    The next six months will tell the future. We will get the ICPT readout and realize that it is not a NASH drug. There will be no other alternative for late-stage NASH other than a Galectin 3 inhibitor. Time will tell if belapectin gets combined with an earlier stage NASH drug.

    Hopefully, in the next 6 months GALT will start its cancer trial and complete its enrollment in the NASH trial.

    I estimate that all this will happen by the November AASLD liver meetings.

    In NASH, one has to measure time in 6-month blocks.

    No concerns with money in GALT. GALT says it needs 50 million. Our COB probably takes that home in PROFITs in a week
  • S
    ScorpionLeather
    This one is just very interesting:

    Long-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levels

    “Conclusion
    The finding of the current study is the first to show that dexamethasone causes an increase in gal-3 levels in myocardium. Our study provides an important step in the development of possible therapeutics by determining that dexamethasone causes an increase in gal-3 levels in the myocardium and raises awareness about the follow-up of patients receiving long-term glucocorticoid therapy.”

    https://link.springer.com/article/10.1007/s10557-022-07344-w
    Bullish
  • r
    rambogalaxyman
    "Dr. Pol Boudes, Chief Medical Officer, stated: “As we hear more about difficulties of reading and interpreting liver biopsies in pre-cirrhotic NASH, the feedback we get from our investigators reinforces our belief that using the prevention of esophageal varices as our primary outcome of efficacy in NAVIGATE is the appropriate efficacy outcome. Patients that are enrolled in our program have advanced to the cirrhotic stage of NASH and have developed portal hypertension, a severe complication of cirrhosis that impacts their prognosis. This also means that many of our patients have low platelet counts, and because this increases the risk of bleeding, it makes a liver biopsy far too dangerous. These are some of the reasons why we do not believe that biopsies are appropriate for patient selection or endpoints in our target population and is also why we even removed the requirement for baseline biopsies in our NAVIGATE trial. Preventing the development of an esophageal varix, on the other hand, is a very relevant and pragmatic clinical outcome. Unfortunately, too many cirrhotic patients bleed from these varices, and this can be a life-threatening event. Preventing the development of varices eliminates this potentially significant adverse outcome related to cirrhosis. We believe the design of the NAVIGATE study is truly innovative and allows us to move clinical research for liver cirrhosis forward.”"

    From the recent biz update. GALT execs have been way ahead of the curve on clinical trial design. Great foresight.
  • S
    ScorpionLeather
    Great presentation this morning. Pol is always very good at explaining, in a way that is easier to understand than the science papers that I like to post.
    Bullish
  • X
    X
    At the moment down in an otherwise up market. I guess our chief medical officer failed to impress potential investors at either of the conferences in London this week. Oh well, maybe it will create greater awareness down the line if things go well. The wording "go well" can be operationally defined as getting things done and on time.
  • X
    X
    $1.19. Unbelievable.

    Perhaps when transparency issues are resolved and there is a new change of heart in communicating with shareholders, we won't keep dropping. Trust is sure hard to maintain or get back once broken. I look forward to the day when management finally "gets it". The question arises, "Is that possible with Joel Lewis at the helm?". One would think that the 10X Fund and Jim Czirr in particular, would be sounding an alarm.
  • Z
    Zuj
    Solid support here. 🦾🦾🦾
    Bullish
  • X
    X
    Ah well that is one step in the right direction! Looking at the main page of Galt's company's website, they still have an old September 2021 presentation listed as their Latest Corporate Presentation BUT if you look on the link Investor Relations link, you will now see a May 26, 2022 presentation. Based upon the recent May 23rd press release, I think it is safe to conclude that this is Dr. Boudes's presentation at the H.C. Wainwright Global Investment Conference just held in London. When you look at the presentation, which I think is interesting because among other things it spends time focusing on Galt's unique approach as a drug developer, it does list a current estimated completion date of ~ Q2 2024 for the interim analysis. Check out the presentation.
  • V
    V
    Time for D.U. to pull a Musk and take this puppy private. Insiders already have ~40%, basically right there anyway.
Advertisement
Advertisement